PTAB sides with Biogen in Forward patent dispute

Forward Pharma A/S (NASDAQ:FWP) lost $5.34 (20%) to $21.51 on Friday after the U.S. Patent Trial and Appeal Board ruled in favor of Biogen Inc. (NASDAQ:BIIB) in a patent interference proceeding concerning IP for multiple sclerosis drug Tecfidera dimethyl fumarate.

Had Forward won the proceeding, it would have been eligible for 10-20% royalties on U.S. Tecfidera sales, beginning in 2021, under an exclusive license from Biogen. With the loss, Forward 's license remains co-exclusive and is paired with a 1% royalty beginning in 2023 (see BioCentury, Jan. 20)...